Insmed Inc (INSM)vsRhythm Pharmaceuticals Inc (RYTM)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
RYTM
Rhythm Pharmaceuticals Inc
$84.62
+2.46%
HEALTHCARE · Cap: $5.64B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 220% more annual revenue ($606.42M vs $189.76M). INSM leads profitability with a -2.1% profit margin vs -103.6%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
RYTM
Avoid30
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Revenue surging 36.9% year-over-year
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Elevated debt levels
Trading at 40.9x book value
ROE of -90.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : RYTM
The strongest argument for RYTM centers on Revenue Growth. Revenue growth of 36.9% demonstrates continued momentum.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : RYTM
The primary concerns for RYTM are EPS Growth, Debt/Equity, Price/Book.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while RYTM is a hypergrowth play — different risk/reward profiles.
RYTM carries more volatility with a beta of 2.15 — expect wider price swings.
RYTM is growing revenue faster at 36.9% — sustainability is the question.
RYTM generates stronger free cash flow (-26M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 30/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Rhythm Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?